Patents Assigned to ADMA BIOLOGICS, INC.
  • Publication number: 20220023339
    Abstract: The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.
    Type: Application
    Filed: August 9, 2021
    Publication date: January 27, 2022
    Applicant: ADMA Biologics, Inc.
    Inventors: James Mond, Adam S. Grossman
  • Patent number: 11084870
    Abstract: The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 10, 2021
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: James Mond, Adam S. Grossman
  • Patent number: 10683343
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 16, 2020
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • Patent number: 10259865
    Abstract: The present invention relates to compositions and methods for the treatment of infection caused by Streptococcus pneumonia. In particular, the invention provides human hyperimmune globulin and compositions thereof for preventing or treating pneumococcal infection. The invention provides methods of producing hyperimmune globulin containing high titers of opsonophagocytic anti-pneumococcal antibodies, compositions containing same, and methods of using the compositions for the prevention and treatment of pneumococcal infection. The invention further provides methods of preventing or treating pneumococcal infection (e.g., upper respiratory infections (e.g., bronchitis, otitis, sinusitis, etc.)) in immunocompromised subjects via administration of hyperimmune globulin compositions of the invention (e.g., containing a high titer of opsonophagocytic anti-pneumococcal antibodies) to immunocompromised subjects.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 16, 2019
    Assignee: ADMA Biologics, Inc.
    Inventors: James Mond, Adam S. Grossman
  • Patent number: 9969793
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: May 15, 2018
    Assignee: ADMA Biologics, Inc.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • Patent number: 9815886
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: November 14, 2017
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • Patent number: 9714283
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 25, 2017
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, Jerrold B. Grossman, James Mond, Dov A. Goldstein
  • Patent number: 9107906
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 18, 2015
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman